ReviewJournal of gynecologic oncology2016
Therapeutic options for management of endometrial hyperplasia.
Review in Journal of gynecologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 218 citations in OpenAlex.
- Pooled it
- A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women.Asian Pacific journal of cancer prevention : APJCP · 2021Trial
- BMI-Dependent Correlations of Sex Hormone Genes with Simple Endometrial Hyperplasia.Life (Basel, Switzerland) · 2026Article
- Polymorphism of theLife (Basel, Switzerland) · 2026Article
- Re-Evaluating the Progesterone Challenge Test as a Physiologic Marker of Endometrial Cancer Risk: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2026Review
- Integrated Signature of Multiple Indices for Preoperative Predictive Stratification of Endometrial Hyperplasia Subtypes: A Retrospective Cohort Study.International journal of women's health · 2026Article
- The significance of papillary architecture in the follow-up biopsies of patients with progestin-treated atypical endometrial hyperplasia.Journal of pathology and translational medicine · 2026Article
- Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management.Cancers · 2025Review
- Exploring the role of circular RNAs in endometrial cancer progression and chemoresistance: Implications for targeted therapies.European journal of medical research · 2025Review
- Multi-omics analysis revealed the addiction to glutamine and susceptibility to de novo lipogenesis of endometrial neoplasm.Science China. Life sciences · 2025Article
- Review
- The value of diffusion-weighted imaging and semi-quantitative dynamic contrast-enhanced MRI in predicting the efficacy of medroxyprogesterone acetate treatment for atypical endometrial hyperplasia and endometrial carcinoma.BMC medical imaging · 2025Article
- Molecular mechanism of tumor-infiltrating immune cells regulating endometrial carcinoma.Genes & diseases · 2025Review
- Resolution of Symptoms of Suspected Nonatypical Endometrial Hyperplasia Using Herbal Medicine Modified Sihogyeji-Tang Monotherapy: A Case Report with Ultrasound Monitoring.Life (Basel, Switzerland) · 2025Article
- Central Serous Chorioretinopathy in Endometriosis Treatment with Progestogen: A Metabolic Understanding.Life (Basel, Switzerland) · 2025Article
- A risk prediction model for endometrial hyperplasia/endometrial carcinoma in premenopausal women.Scientific reports · 2025Article
- Nomogram for predicting pathology upstaging in patients with EIN: is sentinel lymph node assessment useful in these patients?Journal of gynecologic oncology · 2025Article
- Endometrial Atypical Hyperplasia and Risk of Endometrial Cancer.Diagnostics (Basel, Switzerland) · 2024Review
- Diagnostic significance and predictive efficiency of metabolic risk score for fertility-sparing treatment in patients with atypical endometrial hyperplasia and early endometrial carcinoma.Journal of gynecologic oncology · 2024Article
- Correlation between steroid receptor expression and response to progestational therapy in patients with atypical endometrial hyperplasia or cancer.Gynecologic oncology reports · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial hyperplasia (EH) comprises a spectrum of changes in the endometrium ranging from a slightly disordered pattern that exaggerates the alterations seen in the late proliferative phase of the menstrual cycle to irregular, hyperchromatic lesions that are similar to endometrioid adenocarcinoma. Generally, EH is caused by continuous exposure of estrogen unopposed by progesterone, polycystic ovary syndrome, tamoxifen, or hormone replacement therapy. Since it can progress, or often occur coincidentally with endometrial carcinoma, EH is of clinical importance, and the reversion of hyperplasia to normal endometrium represents the key conservative treatment for prevention of the development of adenocarcinoma. Presently, cyclic progestin or hysterectomy constitutes the major treatment option for EH without or with atypia, respectively. However, clinical trials of hormonal therapies and definitive standard treatments remain to be established for the management of EH. Moreover, therapeutic options for EH patients who wish to preserve fertility are challenging and require nonsurgical management. Therefore, future studies should focus on evaluation of new treatment strategies and novel compounds that could simultaneously target pathways involved in the pathogenesis of estradiol-induced EH. Novel therapeutic agents precisely targeting the inhibition of estrogen receptor, growth factor receptors, and signal transduction pathways are likely to constitute an optimal approach for treatment of EH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.